Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2021/2022
The following technology appraisals have been endorsed during 2021/22. Information on technology appraisals endorsed in previous years can be found on the homepage.
March 2022
TA778 - Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
TA777 - Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
TA775 - Dapagliflozin for treating chronic kidney disease
TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction
‘Note this guidance updates and replaces NICE Technology Appraisal TA600, which was endorsed by the DoH in October 2019’.
TA769 - Palforzia for treating peanut allergy in children and young people
February 2022
TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
TA767 - Ponesimod for treating relapsing–remitting multiple sclerosis
TA766 - Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma - Note this guidance updates and replaces NICE Technology Appraisal TA553, which was endorsed by the DoH in March 2019
TA764 - Fremanezumab for preventing migraine
‘Note this guidance updates and replaces NICE Technology Appraisal TA631, which was endorsed by the DoH in July 2020’.
TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
January 2022
TA759 - Fostamatinib for treating refractory chronic immune thrombocytopenia
‘Note this guidance has been updated and replaced by TA835 - Fostamatinib for treating refractory chronic immune thrombocytopenia, which was endorsed by the DoH in November 2022.’
TA758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
TA757 - Cabotegravir with rilpivirine for treating HIV-1
TA756 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
TA755 - Risdiplam for treating spinal muscular atrophy
TA754 - Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
TA753 - Cenobamate for treating focal onset seizures in epilepsy
TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus
‘Note this guidance updates and replaces NICE Technology Appraisal TA397, which was endorsed by the DoH in July 2016’.
December 2021
TA751 - Dupilumab for treating severe asthma with type 2 inflammation
TA748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases
TA744 - Upadacitinib for treating moderate rheumatoid arthritis
November 2021
TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease
TA742 - Selpercatinib for treating advanced thyroid cancer with RET alterations
TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable - ‘Note this guidance updates and replaces NICE Technology Appraisal TA492, which was endorsed by the DoH in February 2019’
TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema
TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy ‘Note this guidance updates and replaces NICE Technology Appraisal TA490, which was endorsed by the DoH in February 2019’
TA735 - Tofacitinib for treating juvenile idiopathic arthritis
TA734 - Secukinumab for treating moderate to severe plaque psoriasis in children and young people
October 2021
TA729 - Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
TA728 - Midostaurin for treating advanced systemic mastocytosis
TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Note this guidance updates and replaces NICE Technology Appraisal TA579, which was endorsed by the DoH in June 2019
September 2021
TA723 - Bimekizumab for treating moderate to severe plaque psoriasis
TA721 - Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
TA720 - Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
August 2021
TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis
TA718 – Ixekizumab for treating axial spondyloarthritis
TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy - Note this guidance updates and replaces NICE Technology Appraisal TA484, which was endorsed by the DoH in January 2019’
TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer
July 2021
TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
‘Note this guidance has been updated and replaced by TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs, which was endorsed by the DoH in September 2022.’
TA710 - Ravulizumab for treating atypical haemolytic uraemic syndrome
TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA707 – Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA706 – Ozanimod for treating relapsing–remitting multiple sclerosis
June 2021
TA705 – Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA699 – Ofatumumab for treating relapsing multiple sclerosis
TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
TA697 - Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
TA696 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
May 2021
TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma Note this guidance partially updates and replaces NICE Technology Appraisal TA657, which was endorsed by the DoH in December
Note this guidance has been updated and replaced by TA946 - Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, endorsed by the DoH in February 2024.
TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Note this guidance updates and replaces NICE Technology Appraisal TA519, which was endorsed by the DoH in February 2019.
TA691 - Avelumab for untreated metastatic Merkel cell carcinoma Note this guidance partially replaces NICE Technology Appraisal TA517, which was endorsed by the DoH in February 2019.’
TA689 - Acalabrutinib for treating chronic lymphocytic leukaemia
April 2021
TA682 - Erenumab for preventing migraine
TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - Note this guidance updates and replaces NICE Technology Appraisal TA557, which was endorsed by the DoH in March 2019.
TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - Note this guidance updates and replaces NICE Technology Appraisal TA558, which was endorsed by the DoH in March 2019.
TA685 - Anakinra for treating Still’s disease
TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - Note this guidance updates and replaces NICE Technology Appraisal TA593, which was endorsed by the DoH in September 2019.
TA688 - Selective internal radiation therapies for treating hepatocellular carcinoma